[go: up one dir, main page]

CY1111750T1 - Νευροτροφικοι παραγοντες - Google Patents

Νευροτροφικοι παραγοντες

Info

Publication number
CY1111750T1
CY1111750T1 CY20111100765T CY111100765T CY1111750T1 CY 1111750 T1 CY1111750 T1 CY 1111750T1 CY 20111100765 T CY20111100765 T CY 20111100765T CY 111100765 T CY111100765 T CY 111100765T CY 1111750 T1 CY1111750 T1 CY 1111750T1
Authority
CY
Cyprus
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
CY20111100765T
Other languages
English (en)
Inventor
Dinah Wen Yee Dr Sah
Teit E Dr Johansen
Anthony Dr Rossomando
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of CY1111750T1 publication Critical patent/CY1111750T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε πολυπεπτίδια νευροτροφικού παράγοντα νευροβλαστίνης, νουκλεϊνικά οξέα που κωδικοποιούν τα πολυπεπτίδια νευροβλαστίνης, και αντισώματα που προσδένονται ειδικά σε πολυπεπτίδια νευροβλαστίνης, καθώς επίσης και σε μεθόδους παρασκευής και μεθόδους χρήσης αυτών.
CY20111100765T 2001-03-12 2011-08-10 Νευροτροφικοι παραγοντες CY1111750T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors
EP07120461A EP1930439B1 (en) 2001-03-12 2002-03-12 Neurotrophic factors

Publications (1)

Publication Number Publication Date
CY1111750T1 true CY1111750T1 (el) 2015-10-07

Family

ID=25189406

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100765T CY1111750T1 (el) 2001-03-12 2011-08-10 Νευροτροφικοι παραγοντες

Country Status (15)

Country Link
US (1) US20020055467A1 (el)
EP (2) EP1373503B1 (el)
JP (2) JP3738008B2 (el)
CN (1) CN1268744C (el)
AT (2) ATE509103T1 (el)
AU (1) AU2002240943B2 (el)
CA (1) CA2440767C (el)
CY (1) CY1111750T1 (el)
DE (1) DE60223511T2 (el)
DK (2) DK1373503T3 (el)
ES (2) ES2296899T3 (el)
NZ (1) NZ528790A (el)
PT (2) PT1373503E (el)
SI (2) SI1373503T1 (el)
WO (1) WO2002072826A2 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
HRP20010036B1 (hr) * 1998-07-14 2010-06-30 Janssen Pharmaceutica N.V. Neurotrofni faktor rasta
BR0116749A (pt) * 2000-12-22 2006-11-28 Genentech Inc usos de artemina ou seu agonista e artigo manufaturado
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2002078730A2 (en) * 2001-03-28 2002-10-10 Biogen, Inc. Use of neublastin polypeptides for treating neuropathic pain
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
RS52910B (sr) * 2003-01-31 2014-02-28 Biogen Idec Ma Inc. Polimerni konjugati mutiranog neublastina
JP4742030B2 (ja) * 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリマーが結合したグリコシル化ニューブラスチン
DE602004019524D1 (de) 2003-06-10 2009-04-02 Nsgene As Verbesserte sezernierung von neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
KR20060095568A (ko) 2003-10-20 2006-08-31 엔에스진 에이/에스 파킨슨병의 생체내 유전자 요법
PT1786454E (pt) * 2004-08-19 2010-08-18 Biogen Idec Inc Variantes de neublastina
CN101123978B (zh) * 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 神经胚素变体
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009045813A1 (en) * 2007-10-01 2009-04-09 Vgx Pharmaceuticals, Inc. Materials and methods for the delivery of biomolecules to cells of an organ
KR101886029B1 (ko) * 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
US20190381138A1 (en) * 2018-05-17 2019-12-19 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy
JP7504367B2 (ja) 2021-05-18 2024-06-24 株式会社Ｌｔｔバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
ATE335003T1 (de) 1996-05-08 2006-08-15 Biogen Idec Inc Ret-ligand 3 (retl3), um neurales und renales wachstum zu stimulieren
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
ES2287020T3 (es) * 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.

Also Published As

Publication number Publication date
SI1373503T1 (sl) 2008-04-30
ES2366610T3 (es) 2011-10-21
EP1373503A2 (en) 2004-01-02
AU2002240943B2 (en) 2007-05-10
CA2440767C (en) 2012-05-29
EP1373503B1 (en) 2007-11-14
EP1930439B1 (en) 2011-05-11
WO2002072826A3 (en) 2003-04-10
ATE509103T1 (de) 2011-05-15
AU2002240943A2 (en) 2002-09-24
CA2440767A1 (en) 2002-09-19
US20020055467A1 (en) 2002-05-09
DE60223511D1 (de) 2007-12-27
PT1930439E (pt) 2011-07-25
PT1373503E (pt) 2008-02-26
ATE378353T1 (de) 2007-11-15
NZ528790A (en) 2004-06-25
DK1930439T3 (da) 2011-08-29
CN1509333A (zh) 2004-06-30
DK1373503T3 (da) 2008-03-25
DE60223511T2 (de) 2008-10-23
EP1930439A1 (en) 2008-06-11
ES2296899T3 (es) 2008-05-01
HK1120556A1 (en) 2009-04-03
JP2005198656A (ja) 2005-07-28
CN1268744C (zh) 2006-08-09
JP2004531242A (ja) 2004-10-14
WO2002072826A2 (en) 2002-09-19
SI1930439T1 (sl) 2011-09-30
JP3738008B2 (ja) 2006-01-25

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
ATE522609T1 (de) Neurotrophe faktoren
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1015585T3 (da) TIE ligandhomologer
ATE394484T1 (de) Smad 6 und dessen anwendungen
IS8016A (is) Prótín sem bindast viðtaka NOGO
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
ATE390482T1 (de) Interleukin-1 hy2. mittel und verfahren
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
DE60200162D1 (de) Härtungszusammensetzung
EA200100110A1 (ru) Нейротрофические факторы
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
NO20033452D0 (no) Polynukleotid konstrukter for ökt lysin produksjon
DE60217720D1 (de) Kurkumin-zusammensetzung zur heilung von dickdarmpolypen
WO2001021794A3 (en) Smad associating polypeptides